Oncolytics Biotech Reports Strong Pelareorep Data in Pancreatic & Breast Cancers at AACR
ONCY has more than doubled off its 52-week low of $0.326.
Summary
Oncolytics Biotech announced positive clinical data from its GOBLET and AWARE-1 studies for pelareorep, showing significantly improved response rates in pancreatic cancer and immune activation in breast cancer, with abstracts accepted for presentation at AACR 2026.
Key Events · Product Development and Regulatory · ONCY
-
Positive Pancreatic Cancer Data
Pelareorep combination therapy achieved a 62% objective response rate in first-line metastatic pancreatic cancer, which the company states is more than double historical chemotherapy rates.
-
Immune Activation in Pancreatic Cancer
Biomarker data from the GOBLET trial showed patients with an immune activation signature experienced longer median progression-free survival (7.5 months vs. 5.6 months).
-
Immune Conversion in Breast Cancer
Data from the AWARE-1 study in early breast cancer demonstrated pelareorep's ability to drive coordinated anti-tumor immune responses, including tertiary lymphoid structure formation, potentially making immunologically 'cold' tumors more susceptible to immunotherapy.
-
AACR Presentation Acceptance
Two abstracts detailing these positive findings have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026.
Analysis · ONCY · Life Sciences
This 8-K filing highlights significant positive clinical data for Oncolytics Biotech's lead immunotherapy candidate, pelareorep. The GOBLET study in metastatic pancreatic ductal adenocarcinoma demonstrated a 62% objective response rate, which the company states is more than double historical chemotherapy rates, alongside improved progression-free survival for patients with immune activation. This is a critical development given the high unmet medical need in pancreatic cancer. Additionally, data from the AWARE-1 study in early breast cancer showed pelareorep's ability to induce tertiary lymphoid structure formation, converting 'cold' tumors into 'hot' ones, suggesting broad applicability and potential synergy with other immunotherapies. The acceptance of these abstracts for presentation at the prestigious AACR Annual Meeting further validates the findings and provides a strong positive signal for the company's pipeline and future development.
At the time of this filing, ONCY was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $103.4M. The 52-week trading range was $0.33 to $1.51. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.